The performance of the stock price over the year has been up and down, leaving investors with either an optimistic or pessimistic outlook, depending on how they interpret the data. Year to date metric has recorded a gain of 56.59%.However, over the last six months, we can see a weaker performance of 111.21%. Over the last 30 days, the price of VRNA has fallen by 15.98%. And in the last five days, it has surged by 17.27%.
Verona Pharma Plc ADR’s stock market performance has been consistent. The 1-year high for the company’s stock was recorded at $70.40 on 04/29/25, with the lowest value being $11.39 on 05/30/24.
52-week price history of VRNA Stock
A stock’s 52-week price history, including the low and high prices, can offer valuable insights into its current standing and future prospects. Verona Pharma Plc ADR’s current trading price is 3.30% away from its 52-week high, while its distance from the 52-week low is 538.45%. The stock’s price range over this timeframe has been between $11.39 and $70.40. The shares of the Healthcare sector company recorded a trading volume of approximately 2.67 million for the day, which was comparatively higher than the average daily volume of 1.4 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Verona Pharma Plc ADR (VRNA) has experienced a quarterly rise of 36.64% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 6.15B and boasts a workforce of 209 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 56.31, with a change in price of +32.84. Similarly, Verona Pharma Plc ADR recorded 1,337,657 in trading volume during the last 100 days, posting a change of +83.97%.
VRNA’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for VRNA stands at 0.60. Similarly, the long-term debt-to-equity ratio is also 0.59.
VRNA Stock Stochastic Average
The raw stochastic average for Verona Pharma Plc ADR over the last 50 days is presently at 91.73%. This reflects a surge from the raw stochastic average of the previous 20 days, which was noted at 91.73%. Further, the company’s Stochastic %K and %D values for the last 20 days were 94.31% and 92.11%, respectively.
